Pharma Stocks To Buy 2017 Here

: Rose nearly 700% following a lucrative licensing deal with Novartis for its antibody gevokizumab.

The year’s biggest winners were often clinical-stage companies that secured major regulatory wins or licensing deals. pharma stocks to buy 2017

: Delivered a 516% return as it dominated its niche in the metabolic disease market. : Rose nearly 700% following a lucrative licensing

In , the pharmaceutical sector outperformed the broader market, with the SPDR S&P Biotech ETF (XBI) surging approximately 40% , doubling the returns of the S&P 500 . This growth was fueled by significant FDA approvals and high-value partnerships between biotech startups and industry giants. 🚀 Top Performing Pharma & Biotech (2017) In , the pharmaceutical sector outperformed the broader

: Soared over 440% after announcing a gene therapy partnership with Pfizer .

: Held its position as the world's largest pharma company by market cap ($387B in 2017). ⚠️ Key Trends & Risks

While 2017 was a banner year, several headwinds shaped investment strategies: Pharm Exec's Top 50 Companies 2017 | PharmExec